Evidence mapPaperPMID 35453151Full record

ArticleThe Journal of clinical endocrinology and metabolism2022

Obesity and Breast Cancer Risk: The Oncogenic Implications of Metabolic Dysregulation.

Sandra C Naaman, Sherry Shen, Meltem Zeytinoglu, Neil M Iyengar

Open access · bronzeAbstract read
In one paragraph

Article in The Journal of clinical endocrinology and metabolism, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed
4.6field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

28 citing papers in PubMed, 48 citations in OpenAlex.

  1. Article
  2. Metabolic Modulation in Cancer Care: The Potential Role of Glucagon-Like Peptide-1 Receptor Agonists.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2026
    Review
  3. Article
  4. Review
  5. Review
  6. Article
  7. Review
  8. Article
  9. Current issues in molecular biology · 2025
    Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Review
  17. Article
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 1 country.

Sandra C NaamanUniversity of Chicago Medicine, Chicago, IL,USA.
Sherry ShenMemorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID 0000-0001-9566-2864
Meltem ZeytinogluEli Lilly and Company, Indianapolis, IN, USA.ORCID 0000-0002-0158-6109
Neil M IyengarMemorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID 0000-0002-9773-5235
Memorial Sloan Kettering Cancer Center · USEli Lilly (United States) · USUniversity of Chicago · US

Funding

The Patient-Reported Outcomes, Community-Engagement and Language (PRO-CEL) CoreP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · 1985 to 2025
$88.4M
INTERGRATED CLINICAL AND BASIC ENDOCRINOLOGY RESEARCHT32DK007011 · UNIVERSITY OF CHICAGO · 1986 to 2025
$1.7M
Physiology CoreP30DK020595 · UNIVERSITY OF CHICAGO · 2025 to 2025
$1.4M
NCATS NIH HHS UL1 TR000457NCI NIH HHS P30 CA008748NCI NIH HHS R01 CA235711NIDDK NIH HHS P30 DK020595NIDDK NIH HHS T32 DK007011NIH HHS 1R01CA235711
6 · The paper itself

Abstract

contextBreast cancer is increasing in prevalence in parallel with rising rates of obesity worldwide. Obesity is recognized as a leading modifiable risk factor for the development of breast cancer; however, this association varies considerably by clinicopathologic features, and the underlying mechanisms are complex. EVIDENCE ACQUISITION: Pubmed literature search using combinations of "obesity," "breast cancer risk," "diet," "exercise," "weight gain," "weight loss," "adipose tissue inflammation," "crown-like structure," "immune markers," "metformin," "gliflozins," "SGLT-2i," "GLP1-RA," and related terms. EVIDENCE SYNTHESIS: Elevated body mass index and weight gain are associated with increased risk of postmenopausal, hormone receptor-positive breast cancer. Emerging evidence suggests that adverse measures of body composition in individuals of any weight can also confer increased breast cancer risk. Mechanistically, various factors including altered adipokine balance, dysfunctional adipose tissue, dysregulated insulin signaling, and chronic inflammation contribute to tumorigenesis. Weight loss and more specifically fat mass loss through lifestyle and pharmacologic interventions improve serum metabolic and inflammatory markers, sex hormone levels, and measures of breast density, suggesting a link to decreased breast cancer risk.

conclusionIncorporating markers of metabolic health and body composition measures with body mass index can capture breast cancer risk more comprehensively. Further studies of interventions targeting body fat levels are needed to curb the growing prevalence of obesity-related cancer.

Indexed as

Breast NeoplasmsBody Mass IndexCarcinogenesisFemaleHumansInflammationObesityRisk FactorsWeight GainWeight Lossbody mass indexbreast cancermetabolicobesity

Identifiers

PMID35453151
PMCPMC9282365
OpenAlexW4224250641

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.